Global Anthracyclines Market, By Drugs (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin), Dosage (Powder, Capsule, Solution, Injection, Suspension, Others), Route of Administration (Oral, Intravesical, Intravenous, Other), Mechanism of Action (Enzyme Interaction, DNA Intercalation, Reactive Oxygen Species (ROS), DNA Adduct Formation), Application (Acute lymphocytic leukemia, Acute myelogenous leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Bladder cancer, Breast cancer, Other metastatic cancers), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Anthracyclines Market Analysis and Size
Cancer is the top cause of death worldwide. According to the data published by the WHO in March 2021, numerous cancer types will have caused approximately 10 million deaths in 2020. Governments of several countries are taking several initiatives to spread awareness and introduce new therapy methods for cancer, which may boost the market growth during the forecast period. With increasing cancer incidence and growing government support as funding, guidance, and assistance, developing countries are providing major growth opportunities to manufacturers operating in the market.
Data Bridge Market Research analyses a growth rate in the anthracyclines market in the forecast period 2023-2030. The expected CAGR of anthracyclines market is tend to be around 6.6% in the mentioned forecast period. The market was valued at USD 1,390.64 million in 2022, and it would grow upto USD 2318.85 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Anthracyclines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, Valrubicin), Dosage (Powder, Capsule, Solution, Injection, Suspension, Others), Route of Administration (Oral, Intravesical, Intravenous, Other), Mechanism of Action (Enzyme Interaction, DNA Intercalation, Reactive Oxygen Species (ROS), DNA Adduct Formation), Application (Acute lymphocytic leukemia, Acute myelogenous leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, Bladder cancer, Breast cancer, Other metastatic cancers),End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (U.K.), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), GSK plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Pfizer Inc (U.S.), Meiji Holdings Co., Ltd. (Japan), MicroBiopharm Japan Co., Ltd.(Japan), Synbias Pharma (Switzerland), Hikma Pharmaceuticals PLC (U.K.), Cumberland Pharmaceuticals Inc (U.S.), Cadila Pharmaceuticals (India), Cipla Inc. (India)
|
|
Market Opportunities
|
|
Market Definition
Anthracycline is a type of antibiotic that is extracted from numerous types of Streptomyces bacteria. They are used for the treatment of various types of cancer. It damages the DNA of cancer cells and stop its function. This can be done either by intercalating into the base pairs in the DNA minor grooves or by causing free radical damage of the ribose in the DNA. Daunorubicin, doxorubicin, and epirubicin are some of the top examples of anthracyclines.
Global Anthracyclines Market Dynamics
Drivers
- Increasing Prevalence of Cancer
In 2020, WHO reported that cancer is a leading cause of death globally, accounting for approximately 10 million deaths. The most common cancers in 2020 were breast (2.26 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); lung (2.21 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases). Thus, this boosts the market growth.
- Increasing Rate of Drug Approvals
There have been numerous drug approvals for the treatment of cancer. For instance, in October 2021, Padagis, in partnership with Ayana Pharma Ltd, received U.S. FDA approval to launch its AB-rated generic version of Doxil (Doxorubicin Liposome Injection).
Opportunities
- Growing Schemes and R&D Activities
Governments of several countries are taking numerous initiatives to spread awareness and introduce new therapy methods for cancer, that may boost the market growth during the forecast period. For instance, the National Comprehensive Cancer Control Program, in 2020, provided funding, guidance, and technical assistance to support programs implementing plans to prevent and control cancer, that may provide opportunities for major market players to launch new products into the market and boost the market growth. Therefore, the above mentioned factors are projected to boost the market considerably.
- Increasing Health Expenditure For Treatment Processes
Numerous government funding for cancer prevention in several countries offers major growth opportunities for the market. For instance, in June 2020, the National Institutes of Health granted approximately US$ 3.5 million to the University of Missouri School of Medicine to study a pre-treatment for chemotherapy which could protect cancer patients from therapy-induced heart problems.
Restraints/Challenges
- Side Effects of
There are several side-effects that are associated with the different types of anthracyclines. Effects such as darkening or redness of the skin (if you recently had radiation treatment), fast or irregular heartbeat, fever or chills, joint pain are associated with these drugs.
This anthracyclines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anthracyclines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anthracyclines Market
COVID-19 impacted every aspect of the healthcare industry, such as the market for doxorubicin, with major disruptions to businesses and economic activities globally. The COVID-19 pandemic affected healthcare systems worldwide, interrupting usual care in numerous healthcare facilities and exposing vulnerable cancer patients to major risks. A study titled ‘Impact of COVID-19 on cancer care in India: a cohort study,’ published in 2021, collected data on several new patient registrations, number of patients visiting outpatient clinics, hospital admissions, daycare admissions for chemotherapy, minor and major surgeries, patients accessing radiotherapy, and diagnostic tests increased.
Recent Developments;
- In 2021, Genentech announced positive results from the pivotal Phase III POLARIX trial investigating Polivy in combination with Rituxan plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus Rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). The trial met the primary endpoint by demonstrating considerably improved and clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL).
Global Anthracyclines Market Scope
The anthracyclines market is segmented on the basis of drugs, dosage, mechanism of action, application, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Daunorubicin
- Doxorubicin
- Epirubicin
- Idarubicin
- Mitoxantrone
- Valrubicin
Dosage
- Powder
- Capsule
- Solution
- Injection
- Suspension
- Others
Mechanism of Action
- Enzyme Interaction
- DNA Intercalation
- Reactive Oxygen Species (ROS)
- DNA Adduct Formation
Application
- Acute lymphocytic leukemia
- Acute myelogenous leukemia
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Bladder cancer
- Breast cancer
- Other metastatic cancers
Route of Administration
- Oral
- Intravesical
- Intravenous
- Other
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Anthracyclines Market Regional Analysis/Insights
The anthracyclines market is analyzed and market size insights and trends are provided by drugs, dosage, mechanism of action, application, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the anthracyclines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for anthracyclines market throughout the forecasted period due to the presence of major key players, continuous technological development, well-developed healthcare sector, increasing prevalence of cancer and increasing awareness in this region.
Asia-Pacific dominates the market due to the increasing research and development activities, rising investment in the healthcare sector, growing awareness, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anthracyclines Market Share Analysis
The anthracyclines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anthracyclines market
Key players operating in the anthracyclines market include:
- AstraZeneca (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co., Inc. (U.S.)
- Lilly (U.S.)
- Amgen Inc. (U.S.)
- GSK plc (U.K.)
- Johnson & Johnson Services, Inc. (U.S.)
- Pfizer Inc (U.S.)
- Meiji Holdings Co., Ltd.(Japan)
- MicroBiopharm Japan Co., Ltd.(Japan)
- Synbias Pharma (Switzerland)
- Hikma Pharmaceuticals PLC (U.K.)
- Cumberland Pharmaceuticals Inc (U.S.)
- Cadila Pharmaceuticals (India)
- Cipla Inc. (India)
SKU-